Inhibition of class II histone deacetylases in the spinal cord attenuates inflammatory hyperalgesia.
BACKGROUND
Several classes of histone deacetylases (HDACs) are expressed in the spinal cord that is a critical structure of the nociceptive pathway. HDAC-regulated histone acetylation is an important component of chromatin remodeling leading to epigenetic regulation of gene transcription. To understand the role of histone acetylation in epigenetic regulation of pathological pain, we have studied the impact of different classes of HDACs in the spinal cord on inflammatory hyperalgesia induced by complete Freund's adjuvant (CFA).


RESULTS
We intrathecally applied inhibitors specific to different classes of HDACs and evaluated their impact on inflammatory hyperalgesia. Pre-injected inhibitors targeting class I as well as II (SAHA, TSA, LAQ824) or IIa (VPA, 4-PB) HDACs significantly delayed the thermal hyperalgesia induced by unilateral CFA injection in the hindpaw. Existing hyperalgesia induced by CFA was also attenuated by the HDAC inhibitors (HDACIs). In contrast, these inhibitors did not interfere with the thermal response either in naïve animals, or on the contralateral side of inflamed animals. Interestingly, MS-275 that specifically inhibits class I HDACs failed to alter the hyperalgesia although it increased histone 3 acetylation in the spinal cord as SAHA did. Using immunoblot analysis, we further found that the levels of class IIa HDAC members (HDAC4, 5, 7, 9) in the spinal dorsal horn were upregulated following CFA injection while those of class I HDAC members (HDAC1, 2, 3) remained stable or were slightly reduced.


CONCLUSIONS
Our data suggest that activity of class II HDACs in the spinal cord is critical to the induction and maintenance of inflammatory hyperalgesia induced by CFA, while activity of class I HDACs may be unnecessary. Comparison of the effects of HDACIs specific to class II and IIa as well as the expression pattern of different HDACs in the spinal cord in response to CFA suggests that the members of class IIa HDACs may be potential targets for attenuating persistent inflammatory pain.
Bai
Guang
G
Department of Neural and Pain Sciences, University of Maryland, Baltimore, Maryland 21117, USA. gbai@umaryland.edu
Wei
Dong
D
Zou
Shiping
S
Ren
Ke
K
Dubner
Ronald
R
D000107:Acetylation / Q000187:drug effects; D000818:Animals; D005620:Freund's Adjuvant; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism*; D006930:Hyperalgesia / Q000150:complications / Q000188:drug therapy*; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D007278:Injections, Spinal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009619:Nociceptors / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology*; D013696:Temperature; D013997:Time Factors
D056572:Histone Deacetylase Inhibitors; D005620:Freund's Adjuvant; D006655:Histone Deacetylases
Cancer Lett. 2009 Aug 8;280(2):211-21
19289255
Mol Cancer Res. 2007 Oct;5(10):981-9
17951399
Epigenetics. 2008 Jan-Feb;3(1):28-37
18326939
CNS Drug Rev. 2003 Summer;9(2):199-216
12847559
Cell. 2007 Feb 23;128(4):693-705
17320507
Pain. 1992 Oct;51(1):5-17
1454405
Pediatrics. 2004 Apr;113(4 Suppl):1076-83
15060202
J Biol Chem. 2002 Feb 22;277(8):6656-66
11739383
Mol Neurobiol. 2009 Aug;40(1):33-45
19396637
Mol Pain. 2010 Jul 23;6:44
20653959
J Neurophysiol. 1996 Nov;76(5):3025-37
8930252
J Neurochem. 2006 Jul;98(1):193-202
16805808
J Neurosci. 2010 Jun 23;30(25):8624-36
20573908
Nature. 2001 Oct 18;413(6857):739-43
11607033
BMC Cancer. 2008 Aug 19;8:243
18713462
Cancer. 2007 Sep 1;110(5):943-54
17647267
J Neurosci. 2010 Mar 31;30(13):4806-14
20357131
Eur J Neurosci. 2004 Jun;19(12):3375-81
15217394
J Neurochem. 2006 Oct;99(2):371-80
17029593
Brief Funct Genomic Proteomic. 2006 Sep;5(3):190-208
16980317
Anticancer Drugs. 2007 Apr;18(4):363-70
17351388
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15179-84
11742087
J Clin Endocrinol Metab. 2005 Aug;90(8):4936-45
15899953
Mol Pharmacol. 2005 Jun;67(6):2032-9
15769948
Mol Pain. 2007 Oct 31;3:32
17974009
Pain. 2004 Aug;110(3):588-596
15288399
J Cell Sci. 2003 Jun 1;116(Pt 11):2117-24
12730288
J Clin Oncol. 2005 Jun 10;23(17):3971-93
15897549
Hum Mol Genet. 2004 Jun 1;13(11):1183-92
15102712
Trends Genet. 2007 Dec;23(12):605-13
18023497
Curr Opin Immunol. 2007 Dec;19(6):694-700
17720468
Learn Mem. 2007 Apr 06;14(4):268-76
17522015
Drug Metab Dispos. 2006 Apr;34(4):612-20
16415118
J Clin Invest. 2005 Nov;115(11):3104-16
16224541
J Neurosci. 2009 Sep 16;29(37):11451-60
19759294
Pain. 1988 Dec;35(3):313-326
2906426
J Neurochem. 2003 Aug;86(4):992-1005
12887696
J Physiol. 2002 Apr 15;540(Pt 2):593-606
11956346
Science. 2009 Aug 14;325(5942):834-40
19608861
J Neurosci. 2008 Nov 12;28(46):11753-9
19005036
J Neurosci. 2001 Mar 1;21(5):1590-9
11222649
J Neurosci. 2004 Feb 18;24(7):1637-45
14973242
J Neurosci. 1998 Jul 15;18(14):5456-62
9651226
Mol Pharmacol. 2009 May;75(5):1014-20
19255242
Bioessays. 2003 Oct;25(10):930-9
14505360
Br J Pharmacol. 2005 Sep;146(2):198-208
15997234
Onkologie. 2008 Nov;31(11):629-33
19145098
Mol Cancer Ther. 2009 Jun;8(6):1409-20
19509247
J Neurosci. 2002 Oct 1;22(19):8422-8
12351716
Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G307-16
11804852
J Neurosci. 1992 Sep;12(9):3671-5
1326611
Biochem J. 2008 Jan 15;409(2):581-9
17868033
Nature. 2007 May 24;447(7143):418-24
17522675
EMBO J. 2001 Dec 17;20(24):6969-78
11742974
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1587-92
16432198
Prog Neurobiol. 2002 Apr;66(5):285-306
12015197
Mol Pharmacol. 2010 Jul;78(1):58-68
20385708
J Neurosci. 2007 Aug 8;27(32):8699-708
17687047
Neuron. 2007 Nov 8;56(3):517-29
17988634
Science. 2010 Feb 19;327(5968):1000-4
20167786
Cell. 2002 Jan 11;108(1):31-43
11792319
Nat Rev Genet. 2009 Jan;10(1):32-42
19065135
Mol Cell Biol. 2001 Sep;21(18):6312-21
11509672
Physiol Behav. 1986;37(5):827-31
3022319
Nat Rev Neurosci. 2006 Oct;7(10):784-96
16988654
J Neurosci. 2007 Jun 6;27(23):6163-73
17553988
PLoS One. 2009 Aug 12;4(8):e6612
19672313
Pain. 2007 Sep;131(1-2):3.e1-4
17574758
Nature. 2007 May 24;447(7143):433-40
17522677
Nat Neurosci. 2006 Apr;9(4):519-25
16501568
Science. 2010 Feb 19;327(5968):1004-7
20167787
Neurotherapeutics. 2007 Jan;4(1):130-7
17199028
Oncologist. 2004;9(5):571-91
15477643
FASEB J. 2008 Oct;22(10):3432-42
18559989
Cancer Lett. 2009 Feb 18;274(2):169-76
18635312
J Mol Neurosci. 2007;31(1):47-58
17416969
Rheumatology (Oxford). 2006 May;45(5):589-94
16332950
Mol Cell Biol. 2005 Apr;25(8):2873-84
15798178
Development. 2004 Jun;131(12):2983-95
15169759
Physiol Behav. 2003 Mar;78(3):375-83
12676272
Curr Pharm Des. 2008;14(6):505-28
18336297
Cancer Lett. 2009 Aug 8;280(2):154-9
19101082